T. Rowe Price Associates’s Aegerion Pharmaceuticals, Inc. AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-81,600
| Closed | -$242K | – | 2589 |
|
|
2016
Q3 | $242K | Sell |
81,600
-100
| -0.1% | -$297 | ﹤0.01% | 2294 |
|
|
2016
Q2 | $122K | Buy |
81,700
+71,000
| +664% | +$106K | ﹤0.01% | 2392 |
|
|
2016
Q1 | $40K | Hold |
10,700
| – | – | ﹤0.01% | 2478 |
|
|
2015
Q4 | $108K | Sell |
10,700
-3,400
| -24% | -$34.3K | ﹤0.01% | 2409 |
|
|
2015
Q3 | $192K | Hold |
14,100
| – | – | ﹤0.01% | 2301 |
|
|
2015
Q2 | $267K | Hold |
14,100
| – | – | ﹤0.01% | 2244 |
|
|
2015
Q1 | $369K | Buy |
14,100
+3,000
| +27% | +$78.5K | ﹤0.01% | 2097 |
|
|
2014
Q4 | $232K | Sell |
11,100
-76,000
| -87% | -$1.59M | ﹤0.01% | 2292 |
|
|
2014
Q3 | $2.91M | Buy |
87,100
+3,200
| +4% | +$107K | ﹤0.01% | 1531 |
|
|
2014
Q2 | $2.69M | Sell |
83,900
-3,355,753
| -98% | -$108M | ﹤0.01% | 1533 |
|
|
2014
Q1 | $159M | Sell |
3,439,653
-418,547
| -11% | -$19.3M | 0.04% | 492 |
|
|
2013
Q4 | $274M | Buy |
3,858,200
+491,900
| +15% | +$34.9M | 0.06% | 356 |
|
|
2013
Q3 | $289M | Sell |
3,366,300
-193,100
| -5% | -$16.6M | 0.07% | 313 |
|
|
2013
Q2 | $225M | Buy |
+3,559,400
| New | +$225M | 0.06% | 362 |
|